A 24-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF6001 DPI in Patients With COPD on a Background Therapy

Trial Profile

A 24-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF6001 DPI in Patients With COPD on a Background Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs CHF 6001 (Primary) ; Budesonide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 1 Feb 2018 to 1 Jan 2018.
    • 21 Nov 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jan 2018.
    • 21 Nov 2017 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top